Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: DR John Riches

Back to Search
Walewska R, Eyre TA, Bloor A, Follows G, Iyengar S, Johnston R, Marr H, Martinez‐Calle N et al. ( 2025 ) . 2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia . British Journal of Haematology vol. 207 , ( 6 ) 2296 - 2313 .
Stiekema LCA, Chou H, Craster A, Wrench B, Bianchi K, Gallipoli P, Davies JK, Gribben JG et al. ( 2025 ) . Analysis of volatile organic compounds in exhaled breath of blood cancer patients identifies products of lipid peroxidation as biomarkers for lymphoma detection . HemaSphere vol. 9 , ( 7 )
Linton K, Collins GP, Forconi F, Shah NN, Dixit K, Munir T, Omer Z, El-Sharkawi D et al. ( 2024 ) . CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies . Clinical Lymphoma Myeloma & Leukemia vol. 24 , s360 - s361 .
Linton K, Collins GP, Forconi F, Shah NN, Dixit K, Munir T, Omer Z, El-Sharkawi D et al. ( 2024 ) . Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies . Clinical Lymphoma Myeloma & Leukemia vol. 24 ,
Hayama M, Riches JC ( 2024 ) . Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia . OncoTargets and Therapy vol. 17 , ( 0 ) 181 - 198 .
D’Avola A, Legrave N, Tajan M, Chakravarty P, Shearer RL, King HW, Kluckova K, Cheung EC et al. ( 2024 ) . PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma . Journal of Clinical Investigation vol. 134 , ( 4 )
Searle E, Forconi F, Linton K, Danilov A, McKay P, Lewis D, El-Sharkawi D, Gleeson M et al. ( 2023 ) . Initial Findings from a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory B Cell Malignancies . Blood vol. 142 , ( Supplement 1 )
Linton K, Forconi F, Lewis D, Riches J, El‐Sharkawi D, Gleeson M, Injac SG, Nandakumar S et al. ( 2023 ) . PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX‐5948, AN ORAL BTK DEGRADER, IN A FIRST‐IN‐HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES . HemaSphere vol. 7 , ( Suppl )
Linton K, Doorduijn J, El‐Sharkawi D, Mous R, Forconi F, Lewis D, Gleeson M, Riches J et al. ( 2023 ) . PB2331: AN ONGOING FIRST‐IN‐HUMAN PHASE 1 TRIAL OF NX‐5948, AN ORAL BRUTON’S TYROSINE KINASE (BTK) DEGRADER, IN PATIENTS WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES . HemaSphere vol. 7 , ( Suppl )
Linton K, Forconi F, Lewis D, Riches J, El‐Sharkawi D, Gleeson M, Injac SG, Nandakumar S et al. ( 2023 ) . Robust Bruton’s tyrosine kinase (BTK) degradation with NX‐5948, an oral BTK degrader, in a first‐in‐human phase 1a trial in relapsed/refractory B cell malignancies . Hematological Oncology vol. 41 , ( S2 ) 573 - 574 .
D’Avola A, Kluckova K, Finch AJ, Riches JC ( 2023 ) . Spotlight on New Therapeutic Opportunities for MYC-Driven Cancers . OncoTargets and Therapy vol. 16 , ( 0 ) 371 - 383 .
Eyre TA, Riches JC ( 2023 ) . The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives . Cancers vol. 15 , ( 9 )
Tausch E, Malcikova J, Riches JC, Edelmann J ( 2023 ) . Editorial: Biology and treatment of high-risk CLL . Frontiers in Oncology vol. 12 ,
Edelmann J, Malcikova J, Riches JC ( 2023 ) . Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era? . Frontiers in Oncology vol. 13 ,
Kluckova K, D'Avola A, Riches JC ( 2022 ) . Advances in Understanding of Metabolism of B-Cell Lymphoma: Implications for Therapy . Cancers vol. 14 , ( 22 )
Keogh RJ, Riches JC ( 2022 ) . The Use of Breath Analysis in the Management of Lung Cancer: Is It Ready for Primetime? . Current Oncology vol. 29 , ( 10 ) 7355 - 7378 .
Bradwell S, Hone L, Thorneycroft K, Lambourne J, Aries JA, Davies JK, Cutino-Moguel T, Riches JC ( 2022 ) . 2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients . Leukemia Research vol. 119 ,
Kluckova K, Clear AJ, D'Avola A, Rassenti LZ, Kipps TJ, Gribben JG, Riches JC ( 2022 ) . B‐cell Receptor Signaling Induced Metabolic Alterations in Chronic Lymphocytic Leukemia Can Be Partially Bypassed by TP53 Abnormalities . HemaSphere vol. 6 , ( 6 )
D'Avola A, Legrave N, Tajan M, Chakravarty P, Shearer RL, King HW, Kluckova K, Cheung EC et al. ( 2022 ) . PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma . Journal of Clinical Investigation vol. 132 , ( 9 )
Walewska R, Parry‐Jones N, Eyre TA, Follows G, Martinez‐Calle N, McCarthy H, Parry H, Patten PEM et al. ( 2022 ) . Guideline for the treatment of chronic lymphocytic leukaemia . British Journal of Haematology vol. 197 , ( 5 ) 544 - 557 .
Caldwell L, Bapat A, Drumright L, Lambourne J, Jimenez-England F, Aries J, Eccersley L, Hallam S et al. ( 2021 ) . Cessation of ciprofloxacin prophylaxis in haemato-oncology patients . Clin Infect Dis
Ali JK, Riches JC ( 2021 ) . The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials . Cancers vol. 13 , ( 23 )
D'Avola A, Legrave N, Tajan M, Chakravarty P, Shearer R, King H, Cheung E, Clear AJ et al. ( 2021 ) . Phosphoglycerate Dehydrogenase Is Required for Germinal Center Formation and Is a Therapeutic Target in MYC- driven Lymphoma . Blood vol. 138 , ( Supplement 1 ) 717 - 717 .
Eyre TA, Riches JC, Patten PEM, Walewska R, Marr H, Follows G, Hillmen P, Schuh AH et al. ( 2021 ) . Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper . British Journal of Haematology vol. 196 , ( 4 ) 864 - 870 .
Vijenthira A, Gong I, Fox TA, Booth S, Cook G, Fattizzo B, Moro FM, Razanamahery J et al. ( 2021 ) . Outcomes of Adult and Pediatric Patients with Hematologic Malignancies and COVID-19: A Systematic Review and Meta-Analysis of 1847 Patients . Blood vol. 136 , ( Supplement 1 ) 39 - 41 .
Riches JC ( 2021 ) . Impact of COVID-19 in patients with lymphoid malignancies . World Journal of Virology vol. 10 , ( 3 ) 97 - 110 .
King HW, Orban N, Riches JC, Clear AJ, Warnes G, Teichmann SA, James LK ( 2021 ) . Single-cell analysis of human B cell maturation predicts how antibody class switching shapes selection dynamics . Science Immunology vol. 6 , ( 56 )
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razanamahery J et al. ( 2020 ) . Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients . Blood vol. 136 , ( 25 ) 2881 - 2892 .
Aries JA, Davies JK, Auer RL, Hallam SL, Montoto S, Smith M, Sevillano B, Foggo V et al. ( 2020 ) . Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology Patients . British Journal of Haematology
King HW, Orban N, Riches JC, Clear AJ, Warnes G, Teichmann SA, James LK ( 2020 ) . Antibody repertoire and gene expression dynamics of diverse human B cell states during affinity maturation .
King HW, Orban N, Riches JC, Clear AJ, Warnes G, Teichmann SA, James LK ( 2020 ) . Antibody Repertoire and Gene Expression Dynamics of Diverse Human B Cell States During Affinity Maturation .
Clear AJ, D'Avola A, Agrawal SG, Rassenti LZ, Kipps TJ, Gribben JG, Riches J ( 2018 ) . B-Cell Receptor Signaling Drives Glycolysis in Chronic Lymphocytic Leukemia Cells . Blood . vol. 132 ,
Riches JC, Gribben JG ( 2016 ) . Mechanistic and Clinical Aspects of Lenalidomide Treatment for Chronic Lymphocytic Leukemia . Current Cancer Drug Targets vol. 16 , ( 8 ) 689 - 700 .
McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M et al. ( 2015 ) . Mechanisms of PD-L1/PD-1–mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model . Blood vol. 126 , ( 2 ) 212 - 221 .
Riches JC, Gribben JG ( 2014 ) . Immunomodulation and Immune Reconstitution in Chronic Lymphocytic Leukemia . Seminars in Hematology vol. 51 , ( 3 ) 228 - 234 .
Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM et al. ( 2014 ) . Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations . Blood . vol. 123 , 4101 - 4110 .
Riches JC, Gribben JG ( 2014 ) . Hanging tough: CMV-specific CD8+ T cells in CLL . Blood vol. 123 , ( 5 ) 608 - 609 .
McClanahan F, Riches JC, Miller S, Ghazaly E, Day W, Capasso M, Gribben J ( 2014 ) . PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least partially reversed in vivo by the immune-modulatory drug lenalidomide . ONCOLOGY RESEARCH AND TREATMENT vol. 37 , 236 - 236 .
Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM et al. ( 2014 ) . Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by <i>NOTCH1</i> mutations . BLOOD vol. 123 , ( 26 ) 4101 - 4110 .
Riches JC, Gribben JG ( 2013 ) . Advances in chimeric antigen receptor immunotherapy for chronic lymphocytic leukemia . Discov Med vol. 16 , ( 90 ) 295 - 302 .
Chen S-S, Herndon TM, Emson C, Riches JC, McClanahan F, Tong T, Yan X-J, Patten PEM et al. ( 2013 ) . Intraclonal Complexity Of CLL Fractions In Cell Proliferation Rates, Gene Expression Signatures, and Responses To Autologous T-Cell Help In Peripheral blood and Secondary Lymphoid Tissues . Blood . vol. 122 ,
Riches JC, Sangaralingam A, Chaplin T, McClanahan F, Iqbal S, Agrawal SG, Ramsay AG, Gribben J ( 2013 ) . NK Cells From CLL Patients Exhibit Down-Regulation Of Interferon Response Genes That Can Be Reversed With Lenalidomide . Blood vol. 122 , ( 21 )
McClanahan F, Miller S, Riches JC, Ghazaly E, Day WP, Capasso M, Gribben J ( 2013 ) . T-Cell Dysfunction In CLL Is Mediated Not Only By PD-1/PD-L1 But Also By PD-1/PD-L2 Interactions - Partial Functionality Is Maintained In PD-1 Defined CD8 Subsets and This Can Be Further Promoted By Ibrutinib Treatment . Blood vol. 122 , ( 21 )
O'Donovan CJ, Ramsay AG, McClanahan F, Rassenti L, Kipps TJ, Gribben J, Riches JC ( 2013 ) . Trisomy 12 CLL Cells Have High Surface Expression Of Integrins Involved In Lymphocyte Trafficking But This Does Not Translate Into Improved LFA-1-Mediated Motility . Blood vol. 122 , ( 21 )
Ene-Obong A, Clear AJ, Watt J, Wang J, Fatah R, Riches JC, Marshall JF, Chin-Aleong J et al. ( 2013 ) . Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma . Gastroenterology vol. 145 , ( 5 ) 1121 - 1132 .
Riches JC, Gribben JG ( 2013 ) . Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications . Hematol Oncol Clin North Am vol. 27 , ( 2 ) 207 - 235 .
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG ( 2013 ) . T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production . Blood vol. 121 , ( 9 ) 1612 - 1621 .
Gribben JG, Riches JC ( 2013 ) . Immunotherapeutic strategies including transplantation: eradication of disease . Hematology Am Soc Hematol Educ Program vol. 2013 , 151 - 157 .
Riches JC, Davies JK, McClanahan F, Fatah R, Iqbal S, Agrawal S, Ramsay AG, Gribben JG ( 2012 ) . Characterizing Immunophenotypic and Functional Pseudo-Exhaustion in T Cells From CLL Patients: The Impact of Lenalidomide . Blood vol. 120 , ( 21 )
Riches JC, Gribben JG ( 2012 ) . Less expensive CARs? . Cytotherapy vol. 14 , ( 7 ) 773 - 774 .
Riches JC, Ramsay AG, Gribben JG ( 2012 ) . Immune reconstitution in chronic lymphocytic leukemia . Curr Hematol Malig Rep vol. 7 , ( 1 ) 13 - 20 .
Riches JC, Ramsay AG, Gribben JG ( 2012 ) . Immune dysfunction in chronic lymphocytic leukemia: the role for immunotherapy . Curr Pharm Des vol. 18 , ( 23 ) 3389 - 3398 .
McClanahan F, Ghirelli C, Greaves P, Riches JC, Coutinho R, Ramsay AG, Gribben JG ( 2012 ) . Inhibitory Ligands CD200, CD270, CD274 and CD276 Are Expressed On Eμ-TCL1 Transgenic Mouse Splenocytes and Are of Potential Relevance to Impaired T-Cell Function in Vivo . BLOOD . vol. 120 ,
Riches JC, Sangaralingam A, Kiaii S, Chaplin T, Cekdemir D, Iqbal S, Ramsay AG, Gribben JG ( 2011 ) . Impact of Lenalidomide on Gene Expression Profiles of Malignant and Immune Cells in Patients with Chronic Lymphocytic Leukemia . Blood vol. 118 , ( 21 )
Riches JC, Davies J, Iqbal S, Fatah R, Agrawal S, Ramsay AG, Gribben JG ( 2011 ) . T-Cells From Patients with CLL Exhibit Phenotypic and Transcription Factor Profiles of Exhaustion Independent of CMV Serostatus . Blood vol. 118 , ( 21 )
Riches JC, Ramsay AG, Gribben JG ( 2011 ) . Chronic lymphocytic leukemia: an update on biology and treatment . Curr Oncol Rep vol. 13 , ( 5 ) 379 - 385 .
Riches JC, Davies J, Iqbal S, Fatah R, Agrawal S, Ramsay AG, Gribben JG ( 2011 ) . T-cells from Patients With CLL Exhibit Phenotypic and Transcription Factor Profiles Of Exhaustion Independent of CMV Serostatus . Blood . vol. 118 , 1780 - 1783 .
Riches JC, Ramsay AG, Gribben JG ( 2010 ) . T-cell function in chronic lymphocytic leukaemia . Semin Cancer Biol vol. 20 , ( 6 ) 431 - 438 .
Riches JC, Gribben JG ( 2009 ) . Interesting times in the diagnosis and treatment of CLL . Oncology (Williston Park) vol. 23 , ( 12 ) 1043 - 1046 .
Bain BJ, Riches J ( 2009 ) . Help with HELLP . American Journal of Hematology vol. 85 , ( 1 ) 70 - 70 .
Riches J, Naresh K, Reid A, Macdonald D ( 2009 ) . Burkitt lymphoma following renal transplantation . British Journal of Haematology vol. 146 , ( 6 ) 583 - 583 .
Riches JC, Sangaralingam A, Kiaii S, Chaplin T, Iqbal S, Ramsay AG, Gribben JG, Cekdemir D . Impact Of Lenalidomide On Gene Expression Profiles Of Malignant And Immune Cells In Patients With Chronic Lymphocytic Leukemia . Conference: 53rd ASH Annual Meeting and Exposition ( San Diego Convention Center ) from: 10/12/2011 to: 13/12/2011 ,
D’Avola A, Legrave N, Tajan M, Chakravarty P, Shearer RL, King HW, Cheung EC, Clear AJ et al. . PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma .
Ali JK, Riches JC . The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials .
Back to Search